Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib plus doxorubicin versus sorafenib alone in advanced hepatocellular carcinoma
2009-011904-47Phase 2Terminated
- Sponsor
- Ethik-Kommission der Medizinischen Fakultät der Martin-Luther-Universität Halle-Wittenberg
- Start
- Jul 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in hepatocellular carcinoma (HCC) comparing Sorafenib monotherapy with Sorafenib plus doxorubicin (2 arms). Primary endpoints: Time to progression and Overall survival. Started Jul 2010; status: terminated.
02
Drugs
sorafenibdoxorubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2009-011904-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011904-47.